Treatment of Genotype 3 Cirrhotic Patients with 12 Weeks Sofosbuvir/Velpatasvir with or without Ribavirin: Real Life Experience from Italy

被引：0

作者：

Pasulo, Luisa ^{[1
]}

Gambato, Martina ^{[2
,3
]}

Spinetti, Angiola ^{[4
]}

D'Ambrosio, Roberta ^{[5
]}

Puoti, Massimo ^{[6
]}

Ciancio, Alessia ^{[7
]}

Di Marco, Vito ^{[8
]}

Calvaruso, Vincenza ^{[9
]}

Colombatto, Piero ^{[10
]}

Brunetto, Maurizia R. ^{[10
]}

Schiavini, Monica ^{[11
]}

Fabris, Paolo ^{[12
]}

Sacchi, Paolo ^{[13
]}

Gulminetti, Roberto ^{[13
]}

Carolo, Giada ^{[14
]}

Scotton, Piergiorgio ^{[15
]}

Pozzan, Caterina ^{[16
]}

Vinci, Maria ^{[6
]}

Vigano, Mauro ^{[17
]}

Lombardi, Andrea ^{[18
]}

Lobello, Salvatore ^{[19
]}

Zuin, Massimo ^{[20
]}

Aghemo, Alessio ^{[21
,22
]}

Rumi, Maria Grazia ^{[17
]}

Manfrin, Vinicio ^{[12
]}

Foppa, Caterina Valeria Uberti ^{[23
]}

Panese, Sandro

Paon, Veronica

Pan, Angelo ^{[24
]}

Spinelli, Ombretta ^{[25
]}

Monforte, Antonella D'Arminio ^{[20
]}

Colli, Agostino ^{[26
]}

Spinzi, Giancarlo ^{[27
]}

Russo, Francesco Paolo ^{[2
,3
]}

Chemello, Liliana ^{[28
]}

Vincenzi, Valter ^{[29
]}

Grossi, Paolo Antonio ^{[30
]}

Buscarini, Elisabetta ^{[31
]}

Soria, Alessandro ^{[32
]}

Menzaghi, Barbara ^{[33
]}

Mendeni, Monia ^{[4
]}

Soffredini, Roberta ^{[5
]}

Colpani, Maria ^{[34
]}

Zaltron, Serena ^{[4
]}

Gori, Andrea ^{[35
]}

Del Poggio, Paolo ^{[1
]}

Giorgini, Alessia ^{[20
]}

Cologni, Giuliana ^{[36
]}

Cartabellotta, Fabio ^{[37
]}

Di Lorenzo, Francesco ^{[38
]}

机构：

[1] Asst Papa Giovanni XXIII, Bergamo HCV Network, Bergamo, Italy

[2] Padova Univ Hosp, Multivisceral Transplant Unit, Padua, Italy

[3] Padova Univ Hosp, Gastroenterol, Padua, Italy

[4] Asst Brescia, Rete HCV Brescia, Brescia, Italy

[5] Univ Milan, Fdn Irccs Ca Granda Osped Maggiore Policlin, Div Gastroenterol & Hepatol, CRC aMea Migliavacca Ctr Liver Dis, Milan, Italy

[6] Asst Grande Osped Metropolitano Niguarda, Hepatitis Ctr, Milan, Italy

[7] Univ Turin, Gastroenterol, Turin, Italy

[8] Univ Palermo, Sez Gastroenterol & Epatol, Dipartimento Biomed Med Interna & Specialist Di B, Palermo, Italy

[9] P Giaccone Univ Hosp, Gastroenterol, Palermo, Italy

[10] Univ Hosp Pisa, Hepatol Unit, Pisa, Italy

[11] Sacco Milano, Fbf, Div Malattie Infett Asst 1, Milan, Italy

[12] Malattie Infett Vicenza, Vicenza, Italy

[13] Irccs Policlin San Matteo, Div Infect & Trop Dis, Pavia, Italy

[14] Azienda Osped Verona, Malattie Infett, Verona, Italy

[15] Azienda Osped Treviso, Malattie Infett, Treviso, Italy

[16] Azienda Osped Venezia, Gastroenterol, Venice, Italy

[17] San Giuseppe Hosp, Hepatol, Milan, Italy

[18] Univ Pavia, Malattie Infett Unita Malattie Infett Trop & Epat, Pavia, Italy

[19] OS Antonio Padova, Gastroenterol, Padua, Italy

[20] Rete HCV Asst Santi Paolo & Carlo, Milan, Italy

[21] Humanitas Res Hosp, Internal Med & Hepatol, Rozzano, MI, Italy

[22] Humanitas Univ, Rozzano, Italy

[23] Osped San Raffaele, Segrate, Italy

[24] Asst Cremona, Infect Dis, Cremona, Italy

[25] Asst Lariana, Med, Como, Italy

[26] Asst Lecco, Med, Lecce, Italy

[27] Valduce Hosp, Como, Italy

[28] Azienda Osped Univ Padova, Clin Med 5, Padua, Italy

[29] Azienda Osped Belluno, Med Gen, Belluno, Italy

[30] Univ Insubria Varese, Malattie Infett, Varese, Italy

[31] Asst Crema, Gastroenterol, Crema, Italy

[32] Asst Monza, San Gerardo Hosp, Infect Dis, Monza, Italy

[33] Busto Arsizio Hosp, Infect Dis, Busto Arsizio, Italy

[34] Asst Papa Giovanni XXIII, Bergamo, Italy

[35] San Gerardo Hosp, Monza, Italy

[36] Asst Papa Giovanni XXIII, Bergamo HCV Network 1, Bergamo, Italy

[37] Osped Buccheri La Feria, UOC Med Interna, Palermo, Italy

[38] Arnas Osped Civ, Infect Dis, Palermo, Italy

[39] Policlin Messina, Med & Epatol, Messina, Italy

[40] Osped Papardo, Infect Dis, Messina, Italy

[41] Osped Modica, Infect Dis, Modica, Italy

[42] Osped Comiso, Comiso, Italy

[43] Rete HCV Asst Santi Paolo & Carlo, Milan, Italy

[44] Asst Sacco, Infect Dis, Milan, Italy

[45] Quovadis Assoc, Bova Marina, Italy

[46] Univ Milan, Milan, Italy

[47] Univ Padua, Dipartimento Med Mol, Padua, Italy

来源：

HEPATOLOGY | 2018年 / 68卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

592

引用

页码：351A / 352A

页数：2

共 50 条

[1] TREATMENT OF 320 GENOTYPE 3 CIRRHOTIC PATIENTS WITH 12 WEEKS OF SOFOSBUVIR/VELPATASVIR WITH OR WITHOUT RIBAVIRIN: REAL LIFE EXPERIENCE FROM ITALY
Pasulo, Luisa
Spinetti, Angiola
Gambato, Martina
D'Ambrosio, Roberta
Calvaruso, Vincenza
Ciancio, Alessia
Vinci, Maria
Carriero, Canio
Colombatto, Piero
Alberti, Alfredo
Fagiuoli, Stefano
HEPATOLOGY, 2019, 70 : 985A - 986A
[2] Treatment of 320 genotype 3 cirrhotic patients with 12 weeks of sofosbuvir/velpatasvir with or without ribavirin: Real life experience from Italy
Pasulo, Luisa
Gambato, Martina
Spinetti, Angiola
D'ambrosio, Roberta
Puoti, Massimo
Ciancio, Alessia
Di Marco, Vito
Calvaruso, Vincenza
Piero, Colombatto
Brunetto, Maurizia
Schiavini, Monica
Sacchi, Paolo
Gulminetti, Roberto
Carolo, Giada
Scotton, Piergiorgio
Pozzan, Caterina
Vinci, Maria
Vigano, Mauro
Lombardi, Andrea
Lobello, Salvatore
Zuin, Massimo Giovanni
Aghemo, Alessio
Rumi, Maria Grazia
Manfrin, Vinicio
Uberti-Foppa, Caterina
Panese, Sandro
Paon, Veronica
Pan, Angelo
Spinelli, Ombretta
Monforte, Antonella d'Arminio
Colli, Agostino
Spinzi, Giancarlo
Russo, Francesco Paolo
Chemello, Liliana
Vincenzi, Valter
Grossi, Paolo Antonio
Buscarini, Elisabetta
Soria, Alessandro
Menzaghi, Barbara
Mendeni, Monia
Soffredini, Roberta
Colpani, Maria
Zaltron, Serena
Gori, Andrea
Giorgini, Alessia
Cologni, Giuliana
Cartabellotta, Fabio
Difrancesco, Lorenzo
Cacciola, Irene
Albanese, Antonio
JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E234 - E235
[3] Treatment of 320 genotype 3 cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: real life experience from Italy
Pasulo, L.
Gambato, M.
Spinetti, A.
D'Ambrosio, R.
Puoti, M.
Ciancio, A.
Di Marco, V.
Calvaruso, V.
Colombatto, P.
Brunetto, M.
Schiavini, M.
Fabris, P.
Sacchi, P.
Gulminetti, R.
Carolo, G.
Scotton, P.
Pozzan, C.
Vinci, M.
Vigano, M.
Lombardi, A.
Lo Bello, S.
Zuin, M.
Aghemo, A.
Rumi, M. G.
Carrara, M.
Manfrin, V.
Uberti-Foppa, C.
Panese, S.
Paon, V.
Pan, A.
Spinelli, O.
Monforte, A. D'Arminio
Colli, A.
Spinzi, G.
Russo, F. P.
Chemello, L.
Vincenzi, V.
Grossi, P.
Buscarini, E.
Cardaci, G.
Soria, A.
Menzaghi, B.
Mendeni, M.
Soffredini, R.
Colpani, M.
Zaltron, S.
Gori, A.
Del Poggio, P.
Giorgini, A.
Cologni, G.
DIGESTIVE AND LIVER DISEASE, 2019, 51 : E16 - E17
[4] EFFICACY AND SAFETY OF 12 WEEKS OF SOFOSBUVIR/VELPATASVIR WITH OR WITHOUT RIBAVIRIN IN GENOTYPE 3 HEPATITIS C VIRUS-INFECTED PATIENTS: A REAL-WORLD STUDY OF CHINA AND SAFETY OF 12 WEEKS OF SOFOSBUVIR/VELPATASVIR WITH OR WITHOUT RIBAVIRIN IN GENOTYPE 3 HEPATITIS C VIRUS-INFECTED PATIENTS: A REAL-WORLD STUDY OF CHINA
Yue, Wei
Liu, Li
Xiao, An
Du, Yingrong
Gao, Jianpeng
Liu, Min
Wang, Yilan
Che, Meng
Guo, Jiaxiang
Li, Junyi
Geng, Jiawei
HEPATOLOGY, 2021, 74 : 589A - 589A
[5] The efficacy of sofosbuvir/velpatasvir/ribavirin in cirrhotic, genotype 3a HCV patients, previously failures to sofosbuvir/daclatasvir/ribavirin combination
Dimitroulopoulos, D.
Karatapanis, S.
Kypreos, D.
Malahias, A.
Tsamakidis, K.
Xinopoulos, D.
JOURNAL OF VIRAL HEPATITIS, 2018, 25 : 71 - 71
[6] Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy
Umberto Restelli
Alfredo Alberti
Adriano Lazzarin
Marzia Bonfanti
Carmela Nappi
Davide Croce
The European Journal of Health Economics, 2018, 19 : 37 - 44
[7] TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 3 INFECTION WITH OR WITHOUT CIRRHOSIS WITH SOFOSBUVIR AND VELPATASVIR WITH OR WITHOUT RIBAVIRIN
Bherwani, Sonny
Saumya, A. S.
Vyas, Kaushal
Narang, Sushil
Pandav, Nilesh
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 140 - 140
[8] High SVR rates in patients with and without cirrhosis treated in real life with Sofosbuvir/Velpatasvir (SOF/VEL) combination for 12 weeks without Ribavirin (RBV)
Mangia, A.
Piazzolla, V.
Losappio, R.
Mazzola, M.
Visaggi, E.
Bacca, D.
Sogari, F.
Potenza, D.
Santoro, R.
Carraturo, I.
Tagarielli, V.
Lauletta, G.
Giannelli, A.
Gesualdo, A.
Minerva, N.
JOURNAL OF HEPATOLOGY, 2018, 68 : S273 - S274
[9] REAL LIFE DATA ON SOFOSBUVIR/LEDIPASVIR plus RIBAVIRIN FOR 12 WEEKS IN GENOTYPE 3 PATIENTS IN THE NORTH EAST OF SCOTLAND
Dundas, P.
Fraser, A.
English, S.
McLeman, L.
GUT, 2016, 65 : A272 - A272
[10] SOFOSBUVIR plus PEGINTERFERON/RIBAVIRIN FOR 12 WEEKS VS SOFOSBUVIR plus RIBAVIRIN FOR 16 OR 24 WEEKS IN GENOTYPE 3 HCV INFECTED PATIENTS AND TREATMENT-EXPERIENCED CIRRHOTIC PATIENTS WITH GENOTYPE 2 HCV: THE BOSON STUDY
Foster, G. R.
Pianko, S.
Cooper, C.
Brown, A.
Forton, D.
Nahass, R. G.
George, J.
Barnes, E.
Brainard, D. M.
Massetto, B.
Lin, M.
McHutchison, J. G.
Subramanian, G. M.
Agarwal, K.
JOURNAL OF HEPATOLOGY, 2015, 62 : S259 - S260

← 1 2 3 4 5 →